Use of Oral Cholera Vaccine in Haiti: A Rural Demonstration Project

被引:60
作者
Ivers, Louise C. [1 ]
Teng, Jessica E. [1 ]
Lascher, Jonathan [2 ]
Raymond, Max [3 ]
Weigel, Jonathan [4 ]
Victor, Nadia [3 ]
Jerome, J. Gregory [5 ]
Hilaire, Isabelle J. [5 ]
Almazor, Charles P. [6 ]
Ternier, Ralph [7 ]
Cadet, Jean [8 ]
Francois, Jeannot [8 ]
Guillaume, Florence D. [9 ]
Farmer, Paul E. [4 ]
机构
[1] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA
[2] Partners Hlth, Haiti Programs Dept, Boston, MA USA
[3] Zanmi Lasante, Programs Dept, St Marc, Haiti
[4] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA
[5] Zanmi Lasante, Monitoring & Evaluat, St Marc, Haiti
[6] Zanmi Lasante, Clin Serv, St Marc, Haiti
[7] Zanmi Lasante, Community Hlth Programs, St Marc, Haiti
[8] Minist Hlth & Populat, Expanded Immunizat Program, Port Au Prince, Haiti
[9] Minist Hlth & Populat, Port Au Prince, Haiti
关键词
OUTBREAKS; EPIDEMIC; SAFETY;
D O I
10.4269/ajtmh.13-0183
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
A cholera epidemic has claimed the lives of more than 8,000 Haitians and sickened 650,000 since the outbreak began in October 2010. Early intervention in the epidemic focused on case-finding, treatment, and water and sanitation interventions for prevention of transmission. Use of oral cholera vaccine (OCV) as part of a complementary set of control activities was considered but initially rejected by policymakers. In December 2011, the Minister of Health of Haiti called for a demonstration of the acceptability and feasibility of the use of OCV in urban and rural Haiti. This paper describes the collaborative activity that offered OCV to one region of the Artibonite Department of rural Haiti in addition to other ongoing treatment and control measures. Despite logistics and cold chain challenges, 45,417 persons were successfully vaccinated with OCV in the region, and 90.8% of these persons completed their second dose.
引用
收藏
页码:617 / 624
页数:8
相关论文
共 50 条
  • [41] Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial
    McCarty, James M.
    Lock, Michael D.
    Bennett, Sean
    Hunt, Kristin M.
    Simon, Jakub K.
    Gurwith, Marc
    VACCINE, 2019, 37 (11) : 1389 - 1397
  • [42] Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trial
    Khan, Ashraful Islam
    Ali, Mohammad
    Lynch, Julia
    Kabir, Alamgir
    Excler, Jean-Louis
    Khan, Md. Arifuzzaman
    Islam, Md. Taufiqul
    Akter, Afroza
    Chowdhury, Fahima
    Saha, Amit
    Khan, Iqbal Ansary
    Desai, Sachin N.
    Kim, Deok Ryun
    Saha, Nirod Chandra
    Singh, Ajit P.
    Clemens, John D.
    Qadri, Firdausi
    BMC INFECTIOUS DISEASES, 2019, 19
  • [43] Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trial
    Ashraful Islam Khan
    Mohammad Ali
    Julia Lynch
    Alamgir Kabir
    Jean-Louis Excler
    Md. Arifuzzaman Khan
    Md. Taufiqul Islam
    Afroza Akter
    Fahima Chowdhury
    Amit Saha
    Iqbal Ansary Khan
    Sachin N. Desai
    Deok Ryun Kim
    Nirod Chandra Saha
    Ajit P. Singh
    John D. Clemens
    Firdausi Qadri
    BMC Infectious Diseases, 19
  • [44] Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial
    Cordero De Los Santos, Lina
    Feris-Iglesias, Jesus
    D'Cor, Naveena Aloysia
    Midde, Venkata Jayanth
    Patnaik, Badri Narayan
    Thollot, Yael
    Rasuli, Anvar
    Desauziers, Eric
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (06) : 1403 - 1411
  • [45] Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas
    Letson, G. William
    Singhasivanon, Pratap
    Fernandez, Eduardo
    Abeysinghe, Nihal
    Jose Amador, Juan
    Margolis, Harold S.
    Edelman, Robert
    HUMAN VACCINES, 2010, 6 (10): : 802 - 809
  • [46] Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5 years of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccine
    Chowdhury, Fahima
    Bhuiyan, Taufiqur Rahman
    Akter, Afroza
    Bhuiyan, Md Saruar
    Khan, Ashraful Islam
    Tauheed, Imam
    Ahmed, Tasnuva
    Ferdous, Jannatul
    Dash, Pinki
    Basher, Salima Raiyan
    Al Hakim
    Lynch, Julia
    Kim, Jerome H.
    Excler, Jean-Louis
    Kim, Deok Ryun
    Clemens, John D.
    Qadri, Firdausi
    VACCINE, 2020, 38 (07) : 1753 - 1761
  • [47] Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12-17 Years in the United States
    McCarty, James M.
    Cassie, David
    Bedell, Lisa
    Lock, Michael D.
    Bennett, Sean
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2021, 104 (05) : 1758 - 1760
  • [48] Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age
    Qadri, F
    Ahmed, T
    Ahmed, F
    Sack, RB
    Sack, DA
    Svennerholm, AM
    VACCINE, 2003, 21 (19-20) : 2394 - 2403
  • [49] Feasibility, coverage and cost of oral cholera vaccination conducted by icddr,b using the existing national immunization service delivery mechanism in rural setting Keraniganj, Bangladesh
    Khan, Ashraful Islam
    Khan, Iqbal Ansary
    Siddique, Shah Alam
    Rahman, Anisur
    Islam, Md. Taufiqul
    Bhuiya, Md Amirul Islam
    Saha, Nirod Chandra
    Biswas, Prasanta Kumar
    Saha, Amit
    Chowdhury, Fahima
    Qadri, Firdausi
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (06) : 1302 - 1309
  • [50] Preclinical immunogenicity and protective efficacy of an oral Helicobacter pylori inactivated whole cell vaccine and multiple mutant cholera toxin: A novel and non-toxic mucosal adjuvant
    Holmgren, Jan
    Nordqvist, Stefan
    Blomquist, Margareta
    Jeverstam, Frida
    Lebens, Michael
    Raghavan, Sukanya
    VACCINE, 2018, 36 (41) : 6223 - 6230